Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.
Also called NCT04607122
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 400 participants
- Sponsor
- CMC Ambroise Paré
- Registry
-
NCT04607122 -
2019-004829-25
-
- Main results
- Low dose of landiolol does not prevent postoperative atrial fibrillation after cardiac surgery in non-Asian patients: a multicentre randomised study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT04607122. Randomized; quadruple masking; primary purpose prevention. Start 2021-01-27 (actual); primary completion 2023-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery
- Acronym
- LANDIPROTEC
- Condition
- Atrial Fibrillation
- Condition
- Cardiac Surgery
- Intervention (Drug)
- Landiolol
- Intervention (Drug)
- Saline
- Lead sponsor
- CMC Ambroise Paré
Record details
- Record id
cardio:ct-nct04607122- Content hash
2e0ea01f9b63f82d1b29c14563a7373c85f640ec852fa4c41d18c1df699b0c41